Results 31 to 40 of about 24,917 (198)

Expression analysis of drug-resistant gene (blaOXA-51) in carbapenemases producing Acinetobacter baumannii treated with imipenem/sulbactam combination

Brazilian Journal of Pharmaceutical Sciences, 2021
Drug-resistant Acinetobacter baumannii is a frightening reality. The aim of this study is to examine the expression profiles of blaOXA-51 gene in carbapenemases producing A. baumannii treated with imipenem/sulbactam combination.
Saber Noshadi, Alireza Khodavandi
doaj   +1 more source

Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study

The Lancet Microbe, 2023
Summary Background Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a global threat, but the distribution and clinical significance of carbapenemases are unclear.
Jinnethe Reyes, L. Komarow, Liang Chen, Lizhao Ge, B. Hanson, E. Cober, E. Herc, T. Alenazi, K. Kaye, J. Garcia-Diaz, Lanjuan Li, S. Kanj, Zhengyin Liu, J. Onate, R. Salata, K. Marimuthu, Hainv Gao, Z. Zong, S. Valderrama-Beltrán, Yunsong Yu, P. Tambyah, G. Weston, S. Salcedo, L. Abbo, Q. Xie, Karen Ordóñez, Minggui Wang, M. Stryjewski, J. Munita, D. Paterson, S. Evans, C. Hill, Keri R Baum, R. Bonomo, Barry N. Kreiswirth, M. Villegas, Robin Patel, C. Arias, H. Chambers, V. Fowler, Y. Doi, D. van Duin, M. Satlin   +42 more
semanticscholar   +1 more source

Evaluation of Xpert Carba-R for detecting carbapenemase-producing organisms in South Africa

African Journal of Laboratory Medicine, 2023
This study evaluated the performance of the Xpert Carba-R assay for detecting the five common carbapenemases in carbapenemase-producing organisms in Johannesburg, South Africa between April 2021 and September 2021.
Sanelisiwe T. Duze, Teena Thomas, Tshegofatso Pelego, Sabelle Jallow, Olga Perovic, Adriano Duse   +5 more
doaj   +1 more source

Comparative Activity of Carbapenem Antibiotics Against Gram-Negative Carbapenemase Producers of Different Groups

Антибиотики и Химиотерапия, 2022
The rapid spread of gram-negative bacteria resistance to carbapenems due to the production of carbapenemases requires new treatment options. The activity of carbapenem antibiotic biapenem, recently registered in Russia, against producers of various ...
V. A. Ageevets, O. S. Sulian, A. A. Avdeeva, P. S. Chulkova, V. V. Gostev, I. V. Ageevets, M. V. Golikova, K. N. Alieva, D. P. Gladin, S. V. Sidorenko   +9 more
doaj   +1 more source

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021)

Open Forum Infectious Diseases, 2023
Background As the frequency of metallo-β-lactamase (MBL)-producing Enterobacterales is increasing worldwide, effective antimicrobials to treat the infections caused by these organisms are urgently needed.
H. Sader, R. Mendes, C. Carvalhaes, J. Kimbrough, M. Castanheira   +4 more
semanticscholar   +1 more source

Class A carbapenemases [PDF]

Journal of Antimicrobial Chemotherapy, 2007
Carbapenems, such as imipenem and meropenem, are most often used to treat infections caused by enterobacteria that produce extended-spectrum beta-lactamases, and the emergence of enzymes capable of inactivating carbapenems would therefore limit the options for treatment.
Walther-Rasmussen, J., Høiby, N.
openaire   +2 more sources

Carbapenemase-Producing Enterobacteriaceae [PDF]

Seminars in Respiratory and Critical Care Medicine, 2015
Carbapenemase-producing Enterobacteriaceae (CPE) were almost nonexistent up to the 1990s, but are today encountered routinely in hospitals and other healthcare facilities in many countries including the United States. KPC-producing Klebsiella pneumoniae was the first to emerge and spread globally and is endemic in the United States, Israel, Greece, and
Doi, Yohei, Paterson, David L.
openaire   +5 more sources

In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018

Journal of Global Antimicrobial Resistance, 2021
: Objectives: This study reports the antimicrobial activity of ceftazidime/avibactam (CZA) and comparators against carbapenemase-producing Enterobacterales (N = 1992) and carbapenemase-producing Pseudomonas aeruginosa (N = 784) collected in Africa/Middle
Pattarachai Kiratisin, Krystyna Kazmierczak, Gregory G. Stone   +2 more
doaj   +1 more source

Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017–2019

Journal of Antimicrobial Chemotherapy, 2023
Objectives To assess the global and regional distribution of ESBLs in Enterobacterales and carbapenemases in Enterobacterales and Pseudomonas aeruginosa. Methods Antimicrobial susceptibility of isolates collected from ATLAS (2017–2019) was determined per
A. Gales, G. Stone, D. Sahm, M. Wise, Eric Utt   +4 more
semanticscholar   +1 more source

Infections Caused by Carbapenem-Resistant Enterobacterales: Epidemiology, Clinical Significance, and Possibilities for Antibiotic Therapy Optimization

Антибиотики и Химиотерапия, 2020
The resistance of Enterobacterales to carbapenems can be realized by different mechanisms, but the most common one is enzymatic, associated with the production of carbapenemases.
S. V. Yakovlev, M. P. Suvorova, A. O. Bykov   +2 more
doaj   +1 more source